Endocrinology

ADA 2026: Key Diabetes Trials to Watch

The upcoming ADA 2026 conference will feature pivotal trials in diabetes management, focusing on novel GLP-1 receptor agonists and SGLT2 inhibitors.

FDA Clears OTC CGM for Non-Insulin-Using Children Aged 2+

The FDA has cleared an over-the-counter continuous glucose monitor for children aged 2 years and older who do not use insulin.

Exercise Declined in Patients with Obesity After Starting a GLP-1

Patients with obesity showed reduced physical activity after initiating GLP-1 receptor agonists, according to a recent analysis.

GLP-1 Receptor Agonists Linked to Elevated Hypotension Risk

GLP-1 receptor agonists are associated with an increased incidence of hypotensive events, particularly in patients with pre-existing cardiovascular risk factors.

Classic CAH: New Approaches to Glucocorticoid Dosing

Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.

Low Alkaline Phosphatase: Recognizing Clinical Consequences

Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.

Afirma Molecular Testing: Unique Situations and New Prognostic Development

Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.

Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue

Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.

Endocrinologists' Role in Early Thyroid Eye Disease Recognition

Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.

XLH Adults: Osteomalacia Persists Despite Conventional Therapy

Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.